Should I be concerned about cancer risk with long-term GLP-1 use?

Current evidence does not support increased cancer risk with GLP-1 medications, with one specific exception. The thyroid C-cell tumor signal from rodent studies hasn't translated to human cancer risk despite millions of patients using these medications for years. Large clinical trials and post-marketing surveillance haven't shown increased thyroid cancer rates. For other cancers, some data actually suggests potential benefits: reduced risk of certain obesity-related cancers (breast, colon, endometrial) through weight loss and metabolic improvements; neutral or reduced pancreatic cancer risk (contrary to initial concerns); and ongoing research into colorectal cancer risk reduction. The SELECT cardiovascular outcomes trial specifically monitored cancer rates and found no increase with semaglutide. Real-world data from large health databases consistently shows no cancer signal. The exception remains medullary thyroid carcinoma in patients with specific genetic predispositions (MEN2 syndrome or family history) - these patients should not use GLP-1s. For the general population, cancer concerns shouldn't prevent appropriate GLP-1 use.